ArticleJournal of clinical microbiology2022
Performance of the Reveal Rapid Antibiotic Susceptibility Testing System on Gram-Negative Blood Cultures at a Large Urban Hospital.
Article in Journal of clinical microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 71 citations in OpenAlex.
- Direct rapid antimicrobial susceptibility testing (RAST) from positive blood cultures: Recent advances, challenges, and future directions.Practical laboratory medicine · 2026Review
- Performance of the Qvella FAST system with downstream application of MALDI-TOF-MS, VITEK 2, and β-LACTA test for same-day identification and antimicrobial susceptibility testing of Gram-negative rods directly from positive blood cultures.Microbiology spectrum · 2026Article
- Reducing time-to-result in bloodstream infections: comparative evaluation of VITEK® REVEAL™ and QuickMIC® for rapid phenotypic antimicrobial susceptibility testing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Evaluation of Q-linea ASTar rapid phenotypic antimicrobial susceptibility testing and potential impact in patients with gram-negative bloodstream infections.Microbiology spectrum · 2026Article
- Advancing antimicrobial therapy: evaluating the ASTar (Q-linea) System for rapid AST in Gram-negative bloodstream infections.Microbiology spectrum · 2026Article
- Rapid Microbiological Diagnostics for Sepsis: Narrative Review of Current and Prospective Approaches.Critical care explorations · 2026Review
- Nanomotion-enabled ultra-rapid antibiotic susceptibility testing with magnetic bead-based pathogen enrichment for accelerated sepsis diagnostics.Scientific reports · 2026Article
- Comparison of the VITEK REVEAL AST and Accelerate Pheno systems for fast antimicrobial susceptibility testing of gram-negative blood cultures at a large academic health system.Journal of clinical microbiology · 2026Article
- Clinical impact of rapid antimicrobial susceptibility testing in patients with bacteremia due to gram-negative bacilli.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Article
- Clinical performance of the VITEK REVEAL fast antimicrobial susceptibility test within a real-world workflow for gram-negative bacteremia: comparison with QMAC-dRAST and conventional methods.Microbiology spectrum · 2026Article
- Evaluation of a rapid, direct sample loading electrochemical AST assay with clinical urine samples.Frontiers in microbiology · 2026Article
- Advances in the detection of Drug-Resistant bacteria: current trends and innovations.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Performance comparison and clinical validation of two rapid direct identification and antimicrobial susceptibility testing approaches for pathogens isolated from positive blood cultures in children.Frontiers in cellular and infection microbiology · 2026Article
- Real-life evaluation of BioFire® BCID2 and Vitek® REVEALTM for Gram-negative bloodstream infections in critical care.PloS one · 2026Article
- Comparison of VITEK REVEAL fast antimicrobial susceptibility testing to antibiotic disk diffusion for gram-negative bloodstream infections.Journal of clinical microbiology · 2025Article
- Article
- Emerging technologies for rapid phenotypic antimicrobial susceptibility testing of clinical isolates of bacteria.Journal of clinical microbiology · 2025Review
- Improving time-to-result: head-to-head comparison of three rapid AST systems for Gram-negative bacteremia, including the newly developed VITEK REVEAL.Journal of clinical microbiology · 2025Article
- Direct Disk Diffusion Testing and Antimicrobial Stewardship for Gram-Negative Bacteremia in the Context of High Multidrug Resistance.Antibiotics (Basel, Switzerland) · 2025Article
- Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs.Antibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Timely and effective antibiotic treatment is vital for sepsis, with increasing incidence of antimicrobial-resistant bacteremia driving interest in rapid phenotypic susceptibility testing. To enable the widespread adoption needed to make an impact, antibiotic susceptibility testing (AST) systems need to be accurate, enable rapid intervention, have a broad antimicrobial menu and be easy to use and affordable. We evaluated the Specific Reveal (Specific Diagnostics, San Jose, CA) rapid AST system on positive blood cultures with Gram-negative organisms in a relatively resistant population in a large urban hospital to assess its potential for routine clinical use. One hundred four randomly selected positive blood cultures (Virtuo; bioMérieux) were Gram stained, diluted 1:1,000 in Pluronic water, inoculated into 96-well antibiotic plates, sealed with the Reveal sensor panel, and placed in the Reveal instrument for incubation and reading. The MIC and susceptible/intermediate/resistant category was determined and compared to results from Vitek 2 (bioMérieux) for the 17 antimicrobials available and to Sensititre (Thermo Fisher) for 24 antimicrobials. Performance was also assessed with contrived blood cultures with 33 highly resistant strains. Reveal was in 98.0% essential agreement (EA) and 96.3% categorical agreement (CA) with Sensititre, with just 1.3% very major error (VME) and 97.0%/96.2%/1.3% EA/CA/VME versus Vitek 2. Reveal results for contrived highly resistant strains were equivalent, with EA/CA/VME of 97.7%/95.2%/1.0% with CDC/FDA Antibiotic Resistance Isolate Bank references. Average time to result (TTR) for Reveal was 4.6 h. Sample preparation was relatively low skill and averaged 3 min. We conclude that the Reveal system enables accurate and rapid susceptibility testing of Gram-negative blood cultures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.